The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Jazz Pharmaceuticals plc shares valued at $417,872 were purchased by Winningham Rick E on Aug 08 ’25. At $112.00 per share, Winningham Rick E acquired 3,731 shares.
Also, Kennedy Patrick purchased 3,731 shares, netting a total of over 417,872 in proceeds.
Before that, ENRIGHT PATRICK G had added 3,731 shares to its account. In a trade valued at $417,872, the Director bought Jazz Pharmaceuticals plc shares for $112.00 each.
As published in their initiating research note from Deutsche Bank on July 15, 2025, Jazz Pharmaceuticals plc [JAZZ] has been a Buy and the price target has been revised to $152. Analysts at UBS upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in early March. As of February 26, 2025, Cantor Fitzgerald has decreased its “an Overweight” rating to a “Neutral” for JAZZ. Earlier on February 13, 2025, Wells Fargo upgraded its rating. Their new recommendation was “an Overweight” for JAZZ stock which previously was a “an Equal weight”.
Analyzing JAZZ Stock Performance
On last trading session, Jazz Pharmaceuticals plc [NASDAQ: JAZZ] rose 3.34% to $117.12. The stock’s lowest price that day was $112.53, but it reached a high of $117.21 in the same session. During the last five days, there has been a surge of approximately 10.56%. Over the course of the year, Jazz Pharmaceuticals plc shares have jumped approximately 5.16%. Shares of the company reached a 52-week high of $148.06 on 02/26/25 and a 52-week low of $95.49 on 04/09/25.
Support And Resistance Levels for Jazz Pharmaceuticals plc (JAZZ)
According to the 24-hour chart, there is a support level at 114.00, which, if violated, would cause prices to drop to 110.89. In the upper region, resistance lies at 118.72. The next price resistance is at 120.33. RSI (Relative Strength Index) is 57.43 on the 14-day chart, showing neutral technical sentiment.
Is Jazz Pharmaceuticals plc subject to short interest?
Stocks of Jazz Pharmaceuticals plc saw a sharp steep in short interest on 2025-07-31 dropping by -0.39 million shares to 5.48 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 5.87 million shares. A decline of -7.06% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.86 of the overall float, the days-to-cover ratio (short ratio) decline to 8.86.
Which companies own the most shares of Jazz Pharmaceuticals plc (JAZZ)?
In terms of Jazz Pharmaceuticals plc share price expectations, FactSet research, analysts set an average price target of 200 in the next 12 months, up nearly 76.48% from the previous closing price of $113.33. Analysts anticipate Jazz Pharmaceuticals plc stock to reach 230 by 2025, with the lowest price target being 152. In spite of this, 6 analysts ranked Jazz Pharmaceuticals plc stock as Buy at the end of 2025. On December 12, 2024, Morgan Stanley assigned a price target of “an Overweight” to the stock and upgraded coverage with a $175.
